Four Health and Life Sciences Companies to Present at the Second Health Challenge Pitch Event on Oct. 2
HALIFAX, NS (September 25) – Four Atlantic Canadian health and life sciences companies will present their mental health and wellness solutions virtually during the second Health Challenge Pitch Event on Friday, October 2, beginning at 12pm.
Thanks to support from Nova Scotia Health, Atlantic Canada Opportunities Agency (ACOA), QEII Foundation, and BioNova, one company developing a mental health and/or wellness solution will receive $100,000 and their innovative medical technology will be launched as a proof of concept within Nova Scotia Health and consideration given for scaled deployment.
The competition was created to drive innovation in the health and life sciences space, showcase the exemplary medical technologies coming out of Atlantic Canada, and encourage the adoption of existing technologies to improve the accuracy and level of care health practitioners require to keep people well, and to make concise, life-saving diagnoses and treatments for patients from a physical and mental wellness perspective.
The four companies that will be pitching virtually on Friday, October 2 include:
Pitches will be 10 minutes in length, followed by five minutes for the judges to ask questions. The event is taking place via videoconference and begins at 12pm on Friday, October, 2.
Those interested in watching are encouraged to register for the event on Eventbrite.
“It’s incredibly inspiring to see such strong leadership and innovation from companies across Atlantic Canada, focusing their efforts on developing mental health and wellness solutions. Given the quality and calibre of the applications we received, I am confident these companies will continue to have a tremendous impact on patient care across our region.” – Martha Casey, Volta CEO
“The submissions that were received are incredibly impressive and the fact that these are medtech companies from our Atlantic provinces proves that we have the knowledge, expertise and resources to develop world-class healthcare solutions right here, for our patient population. Nova Scotia Health is a proud partner, supporting health innovation and discovery.”
– Dr. Gail Tomblin Murphy, Vice President, Research, Innovation & Discovery and CNE, Nova Scotia Health
“We’ve worked hard to build a supportive and collaborative ecosystem for the advancement of the health and life sciences industry to support companies like the finalists announced today. Through BioNova’s programs we can continue to support them beyond the Health Challenge.”
– Scott Moffitt, Executive Director, BioNova
“The QEII Foundation is extremely proud to be part of this initiative, addressing the conversation head-on and tackling some of the big needs in our community. Investing in innovative solutions in mental health and wellness is an investment in the health of our community.” – Susan Mullin, President and CEO, QEII Foundation
“The Government of Canada is proud to support the Health Challenge that highlights the extraordinary work Atlantic Canadian businesses are doing to tackle real challenges and create a more robust health care system.”
– Andy Fillmore, Parliamentary Secretary to the Minister of Infrastructure and Communities and Member of Parliament for Halifax, on behalf of the Honourable Mélanie Joly, Minister of Economic Development and Official Languages and Minister responsible for ACOA
Volta (formerly Volta Labs) is one of Canada’s largest innovation hubs, located in downtown Halifax, Nova Scotia. Volta is creating a space where members of the Atlantic Canadian innovation ecosystem can work, connect and learn from one another by accessing co-working space, participating in programs and attending events. Volta has been home to more than 50 startups through its Residency program, which has created more than 300 jobs and raised a combined total of $60-million in equity financing.
About Nova Scotia Health
Nova Scotia Health provides health services to Nova Scotians and a wide array of specialized services to Maritimers and Atlantic Canadians. We operate hospitals, health centres and community-based programs across the province. Our team of health professionals includes employees, doctors, researchers, learners and volunteers. We work in partnership with community groups, schools, governments, foundations and auxiliaries and community health boards. Visit nshealth.ca for more.
BioNova leads the development of Health and Life Sciences in Nova Scotia. Our industry-led sector growth plan, BioFuture 2030, has made us the fastest growing sector in Atlantic Canada. We represent over 100 companies in Nova Scotia who have raised over $65 million in investment dollars since the beginning of 2020.
About QEII Foundation
The QEII Foundation inspires generosity to advance health care at the QEII. With financial support from all levels of the community, the QEII Foundation helps fund new technologies, medical research, innovation and professional education that contribute to life-changing moments experienced every day by patients and their loved ones. By working together with people who share a vision of better health, the Foundation strengthens care delivered at the QEII, improving the health and lives of Atlantic Canadians.
About the Atlantic Canada Opportunities Agency
The Atlantic Canada Opportunities Agency works to create opportunities for economic growth in Atlantic Canada by helping businesses become more competitive, innovative and productive, by working with diverse communities to develop and diversify local economies, and by championing the strengths of Atlantic Canada. Together, with Atlantic Canadians, ACOA is building a stronger economy. For more information, please visit www.acoa-apeca.gc.ca.
For more information, contact:
Kelly Reinsborough, Director, Innovation, Nova Scotia Health
OTTAWA, September 22, 2020 – BioTalent Canada is expanding its successful national Student Work Placement Program (SWPP) to Canadian healthcare for the first time.
Providing wage subsidies to healthcare students builds on BioTalent Canada’s successful track record of delivering SWPP in the bioscience industry since 2017. Over the past three years, with its many wage subsidy programs including SWPP, BioTalent Canada has placed 2,650 students with biotechnology companies across the country.
“The COVID-19 pandemic has been devastating to employment in Canada, including for young people and new graduates,” said Rob Henderson, President and Chief Executive Officer of BioTalent Canada. “Enhancements to the Student Work Placement Program will ensure that young people gain valuable career experience and position them to secure meaningful employment in healthcare.”
“Ensuring a strong economic recovery depends on the success of our students and youth. Programs like the Student Work Placement exist to provide young people with the chance to grow professionally and develop new skills while working in sectors that are in line with their interests and field of study,” said Minister of Employment, Workforce Development and Disability Inclusion Carla Qualtrough. “Our Government’s investment in BioTalent Canada will go a long way in helping young students across the country gain meaningful work experience in the healthcare industry, an industry which is especially important in responding to the current pandemic.”
Since 2017, BioTalent Canada has successfully placed more than 1,600 students in work-integrated learning placements through the SWPP program with more than 350 biotech employers. With this new enhancement, BioTalent Canada will now be able to offer an additional 1,500 placements devoted exclusively to healthcare. These placements may include (but are not limited to) hospitals, clinics, pharmacies, long-term care facilities and dental offices anywhere in Canada.
Under the SWPP program, employers can receive up to $7,500 per placement in wage subsidies to hire a post-secondary student for up to a 16-week student placement opportunity. Enhancements to the SWPP program administered by BioTalent Canada include an expansion of eligibility to part-time students across Canada, and the broadening of the eligibility criteria to include healthcare workers. For more information about the program please visit biotalent.ca/Co-opFunds.
This project is funded in part by the Government of Canada’s Student Work Placement Program through the department of Employment and Social Development Canada.
– 30 –
About BioTalent Canada
BioTalent Canada™ is the HR partner of and catalyst for growth in Canada’s bio-economy. Our engagement with employers, associations, post-secondary institutions, immigrant serving agencies and service providers has built a dynamic network that is strengthening skills, connecting job-ready talent to industry and creating opportunities. Recently awarded a Great Place to Work® Certification, BioTalent Canada practices the same industry standards they recommend to their stakeholders.
Recently, BioTalent Canada was named one of Best Workplaces in Ontario for 2020 and Best Workplaces in Healthcare These distinctions were awarded to BioTalent Canada following a thorough and independent analysis conducted by Great Place to Work®. Direct feedback from employees was provided to Great Place to Work® through a staff survey.
September 14, 2020 by Lou Shuman, DMD, CAGS and Thais Carter of Cellerant Consulting Group
In Combining Botanical Foam with the Latest in LED Innovation, PhotoDynamic is Poised to Revolutionize Home-Based Oral Hygiene for Ortho Patients
Moving from research and development to an operationalized business is a milestone for any company but in the case of PhotoDynamic – a small, Halifax, NS-based firm – bringing its Phyto-Light device and foam to the dental industry isn’t just an institutional milestone. It is groundbreaking for every orthodontist or GP who has dealt with white spot lesions or periodontal damage from the poor home hygiene of orthodontic patients, and a potential game-changer (and I don’t use that word lightly) for the 20% of the population in Canada and the US considered “high plaque formers.”
In the midst of rebooting a clinical trial stalled by COVID-19 earlier this year, we caught up with PhotoDynamic CEO Martin Greenwood to discuss the characteristics that set this product apart and merit a financial investment by the American Association of Orthodontists – the first in the Association’s history.
Health Canada approves DMF Medical’s memsorb™CO2 membrane filtration device for sale in Canada
HALIFAX, Nova Scotia, Canada, September 2020 – DMF Medical Incorporated – a privately held medical device company focused on making anesthesia safer, is pleased to announce that it has received a Class II medical device license from Health Canada to sell its memsorb™ carbon dioxide (CO2) filtration device in the Canadian market. This follows on the heels of successful ISO 13485:2016 and MDSAP certifications earlier this year. This approval is the culmination of years of research, development, and clinical validation of this next-generation solution for general anesthesia.
Dr. Michael Schmidt, Founder and Chief Medical Officer (CMO), expressed his thoughts regarding this revolutionary technology by saying “My goal has always been to make anesthesia safer by bringing technologies like memsorb™ from the bench to the bedside. The approval of memsorb™ in Canada is a meaningful and crucial next step in addressing the ongoing challenges we face in anesthesia, such as our aging patient population, ongoing economic pressures, and our environmental footprint. We are thrilled to have been able to develop this first-of-its-kind technology in Nova Scotia, and are eager to share it with our colleagues across Canada and around the world.”
Dr. David Roach, President, would like to thank the numerous funding partners who have supported the company through the many stages of the commercialization of memsorb™. These include the Atlantic Canada Opportunities Agency (ACOA), the National Research Council of Canada – Industrial Research Assistance Program (NRC-IRAP), Sustainable Development Technologies Canada (SDTC), Next Generation Manufacturing Canada (NGen), the Dalhousie Department of Anesthesia, Pain Management and Perioperative Medicine, BioNova, and the Province of Nova Scotia, without whom this made-in-Canada solution would not have been possible.
memsorb™ is a next generation CO2 removal system for general anesthesia. It uses patented medical membrane technology rather than a chemical reaction to remove CO2 from the breathing circuit of anesthesia machines. memsorb™ provides numerous advantages over current technologies including: longer life, elimination of waste, reduced greenhouse gas emissions, elimination of chemical byproducts, and increased machine reliability.
Appili Therapeutics Inc.’s common shares will begin trading on the main board of the Toronto Stock Exchange on Wednesday, after spending 15 months on the TSX Venture exchange.
The Halifax-based company, which is working on bringing a portfolio of anti-infectious drugs to market, issued a statement Monday saying the change would take place at the start of trading Wednesday. By trading on the main TSX board, the company will have exposure to a broader group of investors, which should make it easier to raise capital.